Oligoastrocytoma: The Vanishing Entity With True Dual Genotype, a Report, its Molecular Profiles and Review of Literature
- PMID: 39699080
- DOI: 10.1177/10668969241300503
Oligoastrocytoma: The Vanishing Entity With True Dual Genotype, a Report, its Molecular Profiles and Review of Literature
Abstract
Isocitrate dehydrogenase (IDH) mutant gliomas are classified as astrocytoma or oligodendroglioma based on the recent application of ATRX mutation, TP53 mutation, and 1p/19q co-deletion. Astrocytomas classically show ATRX and TP53 mutations, whereas oligodendrogliomas are defined by 1p/19q co-deletion. However, there are reports of gliomas that harbor both astrocytoma and oligodendroglioma morphologically and molecularly. Here we present a patient of a 29-year-old woman who presented with a headache and underwent gross total excision. Magnetic resonance imaging showed a right frontal space-occupying lesion with T2 fluid-attenuated inversion recovery mismatch. Histology showed 2 distinct areas of morphology compatible with oligodendroglioma and astrocytoma. Immunohistochemistry showed both components being positive for IDH R132H. Alpha thalassemia/mental retardation syndrome X-linked (ATRX) showed loss of nuclear expression and p53 was strongly positive in the morphologic astrocytoma component, whereas ATRX was retained and p53 was negative in the morphologic oligodendroglioma component. Fluorescence in situ hybridization showed 1p/19q co-deletion in the oligodendroglioma component while co-deletion was absent in the astrocytoma component. TERT mutation was present in the oligodendroglioma component, whereas it was absent in the astrocytoma component. Although rare, gliomas harboring both oligodendroglioma and astrocytoma components in a single tumor exist and show genetically distinct areas.
Keywords: 1p/19q co-deletion; TERT; astrocytoma; oligodendroglioma.
Conflict of interest statement
Declaration of Conflicting InterestsThe authors declared no potential conflicts of interest with respect to the research, authorship, and/or publication of this article.
Similar articles
-
Diagnostic test accuracy and cost-effectiveness of tests for codeletion of chromosomal arms 1p and 19q in people with glioma.Cochrane Database Syst Rev. 2022 Mar 2;3(3):CD013387. doi: 10.1002/14651858.CD013387.pub2. Cochrane Database Syst Rev. 2022. PMID: 35233774 Free PMC article.
-
H3K27me3 immunostaining is diagnostic and prognostic in diffuse gliomas with oligodendroglial or mixed oligoastrocytic morphology.Virchows Arch. 2021 Nov;479(5):987-996. doi: 10.1007/s00428-021-03134-1. Epub 2021 Jun 24. Virchows Arch. 2021. PMID: 34165590 Free PMC article.
-
Diagnostic accuracy of 1p/19q codeletion tests in oligodendroglioma: A comprehensive meta-analysis based on a Cochrane systematic review.Neuropathol Appl Neurobiol. 2022 Jun;48(4):e12790. doi: 10.1111/nan.12790. Epub 2022 Mar 3. Neuropathol Appl Neurobiol. 2022. PMID: 34958131 Free PMC article.
-
Morphologically, genetically and spatially mixed astrocytoma and oligodendroglioma; chronological acquisition of 1p/19q codeletion and CDKN2A deletion: a case report.Brain Tumor Pathol. 2023 Jan;40(1):26-34. doi: 10.1007/s10014-022-00448-z. Epub 2022 Dec 26. Brain Tumor Pathol. 2023. PMID: 36572828
-
1p/19q co-deleted fibrillary astrocytomas: Not everything that is co-deleted is an oligodendroglioma.Ann Diagn Pathol. 2020 Jun;46:151519. doi: 10.1016/j.anndiagpath.2020.151519. Epub 2020 Apr 8. Ann Diagn Pathol. 2020. PMID: 32305004
Cited by
-
A dual-genotype IDH-mutant infiltrating glioma, a real oligoastrocytoma in cerebral hemisphere.IBRO Neurosci Rep. 2025 Feb 25;18:366-369. doi: 10.1016/j.ibneur.2025.02.013. eCollection 2025 Jun. IBRO Neurosci Rep. 2025. PMID: 40092656 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical
Research Materials
Miscellaneous